Clinical trials: Metastatic Colorectal Neoplasms
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
This 2 arm study will assess the efficacy and safety of Avastin in combination with irinotecan + 5-fluorouracil/folinic acid, versus irinotecan + fluorouracil/folinic acid alone, as first line treatment in Chinese patients with…
- Trial name
- NCT00642577
- Testing
- bevacizumab [Avastin], irinotecan, leucovorin
- Where
- 12 sites in China
- Volunteers
- 214 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
This study is being done to select an appropriate TF2 bsMAb dose suitable for pretargeting the 111In/90Y-labeled hapten-peptide (IMP-288).
- Trial name
- NCT01273402
- Testing
- TF2/IMP288
- Where
- United States
- Sponsor
- Gilead Sciences
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- CRYSTAL (NCT00154102)
- Testing
- Cetuximab, FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
- Where
- 154 sites in Argentina, Australia and 28 more
- Volunteers
- 1,221 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients
To evaluate the safety, tolerability, pharmacokinetics and antitumor activity of YYB101 with Irinotecan, patients who are metastatic or recurrent Colorectal Cancer Patients.
- Trial name
- NCT04368507
- Testing
- YYB101
- Where
- 3 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- CellabMED
Non Small Cell Lung Cancer, Breast Cancer
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer.
- Conditions
- Non Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- PTC-IMPACT (NCT06227728)
- Where
- 2 sites in Vietnam
- Volunteers
- 50 people
- Sponsor
- Gene Solutions
Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
The primary purpose of this study is to characterize the safety and tolerability of tucatinib (MK-7119) in Chinese participants with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, gastric or…
- Conditions
- Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
- Trial name
- NCT05382364
- Testing
- Tucatinib
- Where
- 5 sites in China
- Volunteers
- 25 people
- Sponsor
- Pfizer
Colorectal Cancer
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
This randomized, multicenter, open label study will evaluate the safety and efficacy of RO5083945 in combination with FOLFIRI as compared to FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with…
- Trial name
- NCT01326000
- Testing
- FOLFIRI, RO5083945, cetuximab
- Where
- 69 sites in United States, Australia and 7 more
- Volunteers
- 169 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Trial of TG4023 Combined With Flucytosine in Liver Tumors
This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary…
- Trial name
- NCT00978107
- Testing
- MVA-FCU1, flucytosine
- Where
- 6 sites in France
- Volunteers
- 16 people
- Sponsor
- Transgene
Metastatic Colorectal Carcinoma, Neuropathy
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum.
- Trial name
- ASIST (NCT05322590)
- Testing
- BXQ-350
- Where
- 12 sites in United States
- Volunteers
- 195 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Solid Tumor, Colorectal Cancer
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors
- Conditions
- Solid Tumor, Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07589205
- Testing
- Drug: IBI3028
- Where
- China
- Volunteers
- 493 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Colorectal Neoplasms
Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment
This study is for patients with metastatic adenocarcinoma arising from the colon or rectum who have received treatment(s) for metastatic disease with subsequent disease progression.
- Trial name
- NCT00313794
- Testing
- CP-675,206
- Where
- 11 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in…
- Trial name
- NCT05608044
- Testing
- Botensilimab, Balstilimab, Standard of Care
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 234 people
- Sponsor
- Agenus Inc.
Colorectal Neoplasms
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
This study will compare the safety and efficacy of sunitinib in combination with FOLFOX versus bevacizumab in combination with FOLFOX for the treatment of patients with metastatic colorectal cancer who have not been treated…
- Trial name
- NCT00609622
- Testing
- sunitinib, mFOLFOX6, bevacizumab
- Where
- 97 sites in United States, Denmark and 2 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel…
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- ERADIC8 (NCT06395519)
- Testing
- ETX-19477
- Where
- 14 sites in United States
- Volunteers
- 120 people
- Sponsor
- 858 Therapeutics, Inc.
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Colorectal Cancer
A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
This study will assess the efficacy and safety of intravenous Avastin in combination with chemotherapy regimens as second-line treatment of metastatic cancer of the colon or rectum.
- Trial name
- NCT01181609
- Testing
- bevacizumab [Avastin]
- Where
- 16 sites in France
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer (mCRC)
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and…
- Trial name
- CLOVER (NCT06699836)
- Testing
- 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- CytoDyn, Inc.
Colorectal Cancer
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.
- Trial name
- NCT03542877
- Testing
- Oral Tablet: Cabozantinib
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Colorectal Cancer
A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675)
This is a randomized, double-blind, parallel group, placebo-controlled study evaluate the preliminary efficacy and safety of MB-6 (320 mg/capsule, 6 capsules tid) versus placebo in addition to standard chemotherapy in the…
- Trial name
- NCT01047475
- Testing
- MB-6
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- Microbio Co Ltd